摘要
目的:探讨同期放化疗对中晚期鼻咽癌患者的远期临床疗效。方法:选取204例中晚期鼻咽癌患者,分为同期放化疗组102例(研究组)和单纯放疗组102例(对照组),每组再分低危和高危两个亚组,两组放疗方法相同。研究组于放疗前及放疗第4周给予DDP20mg/m2,d1-3,5-FU 500mg/m2,d1-3。结果:研究组和对照组5年总生存率(OS)分别为69.6%和51.0%,差异有统计学意义(P<0.05);5年无进展生存率(PFS)分别为60.8%和44.1%,差异有统计学意义(P<0.05);5年无复发生存率(RFS)分别为88.7%和73.1%,差异有统计学意义(P<0.05);5年无远处转移生存率(DMFS)分别为78.9%和71.2%,差异无统计学意义(P>0.05)。低危亚组患者间的5年OS为80.7%和53.1%,差异有统计学意义(P<0.05)、PFS为68.4%和45.3%,差异有统计学意义(P<0.05)、RFS为95.3%和77.8%,差异有统计学意义(P<0.05)、DMFS为83.7%和75.0%,差异有统计学意义(P>0.05)。结论:同期放化疗可提高中晚期鼻咽癌患者的5年OS、PFS及RFS,但其5年DMFS无明显减少。
Objective. To investigate the long-term clinical effect of the concurrent chemoradiotherapy and the radiotherapy alone on patients with middle or advanced-stage nasopharyngeal carcinoma （NPC）. Methods. 204 NPC patients were divided equally into 2 groups. 102 patients in the experimental group were treated by concurrent chemoradiotherapy and the orther 102 patients in the con trol group by radiotherapy alone. Both groups were furtherly divided into 2 subgroups of low-risk and high-risk; Radiation therapy in both groups was the same. Patients in the experimental group were treated by DDP 20mg/m2, dl-3 and 5-FU 500mg/m2 , dl-3, 4 weeks before and after the radiotherapy. Results： The 5-year overall survival （OS） rate of the experimental group and the control group were 69.6% and 51.0K （P〈0.05） respectively; 5-year progression-free survival （PFS） rate of both groups were 60.8% and 44.1% （P〈0.05） respectively; 5-year recurrence-free survival （RFS） rate of both group were 88.7% and 73.1% （P〈0.05） respectively; 5-year distant metasta- sis-free survival （DMFS） rate of both groups were 78.9% and 71.2% （P〈0.05） respectively. The 5-year OS, PFS, RFS, DMFS of the low-risk subgroup in the experimental group and the control group were 80. 7% and 53. 1% （P〈0. 05）, 68.4% and 45.3% （P〈0. 05）, 95.3% and 77.8% （P d0.05）, 83.7% and 75.0K （P〈0. 05）, respectively. Conclusion. Concurrent chemoradiotherapy can increase the 5-year OS, PFS and RFS of middle or advanced-stage nasopharyngeal NPC, but 5- year DMFS has no significant decrease. In addition, the intensity of chemotherapy should be increased for patients in the high-risk subgroup.
出处
《华夏医学》
CAS
2013年第6期1091-1095,共5页
Acta Medicinae Sinica
基金
广西梧州市科学研究与技术开发计划项目(200702019)
关键词
鼻咽肿瘤
放
化疗
预后
nasopharyngeal carcinoma （NPC）/chemoradiotherapy prognosis
